--- title: Olink® Proteomics Multiplex Analysis White Paper | GENEWIZ from Azenta description: Olink® white paper verifying the quality of Olink's proprietary PEA technology relative to two common multiplex proteomics platforms widely used in protein biomarker research --- [Skip to content](https://web.genewiz.com/whitepaper/olink-proteomics-multiplex-analysis#main-content) [![GENEWIZ](https://web.genewiz.com/hubfs/GENEWIZ%20Brand%20Assets/GENEWIZ%20Logos/2025-04%20Current%20GENEWIZ%20Logos/GENEWIZ_Full-Color_Logo_PublicWeb_200x63.svg "GENEWIZ")](https://www.genewiz.com/) English # Olink® Proteomics Multiplex Analysis White Paper WHITE PAPER ## Multiplex Analysis of Inflammatory Proteins: A Comparative Study Across Multiple Platforms Multiplexing technologies are often challenged by **cross-reactive binding and assay interference**, which can contribute to signal readout and reduce specificity, particularly as the degree of multiplexing increases. These limitations make it difficult to confidently measure inflammatory protein biomarkers across complex biological samples. Olink®’s proprietary **Proximity Extension Assay (PEA)** technology addresses these challenges through a **dual-recognition approach**, using matched antibody pairs labeled with complementary DNA oligonucleotides. A measurable signal is generated only when both antibodies bind the same target protein, helping to minimize off-target effects and improve assay specificity. This white paper presents a **comparative evaluation of Olink technology** relative to two commonly used multiplex proteomics platforms, **Meso Scale Discovery (MSD) and Bio-Rad/Luminex**, that are widely applied in inflammatory protein and cytokine biomarker research. ### What You’ll Learn: - How **cross-reactivity, interference, and multiplex scaling** impact data quality in antibody-based proteomics assays - A head-to-head comparison of **three multiplex proteomics platforms** (Olink, MSD, and Bio-Rad/Luminex) using overlapping inflammatory protein targets - How each platform performs across key analytical metrics, including **detectability, dynamic range, precision (%CV), dilution series parallelism, and linearity** - Practical differences in **sample volume requirements** and assay design considerations for inflammatory biomarker studies ![Olink Whitepaper-1](https://web.genewiz.com/hs-fs/hubfs/2024-03%20GEN%20NGS%20Olink%20Proteomics%20Webpage%20Update/Olink%20Whitepaper-1.png?width=442&name=Olink%20Whitepaper-1.png "Olink Whitepaper-1") ## Download Whitepaper ## Related Services [Olink Proteomics Services](https://www.genewiz.com/public/services/next-generation-sequencing/proteomics) High-sensitivity protein biomarker profiling using proximity extension assay technology. [Clinical Services](https://www.genewiz.com/public/services/clinical-services) Regulatory-compliant laboratory testing to support clinical research and trials. [RNA Sequencing](https://www.genewiz.com/public/services/next-generation-sequencing/whole-genome-sequencing) Comprehensive transcriptome profiling to quantify gene expression and transcript diversity.